Hoese & Co’s Sanofi SNY Stock Holding History

Hoese & Co’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$9.37K	–	176
2023 Q1	$9.37K	Hold	200	–	–	0.01%	127
2022 Q4	$9K	Hold	200	–	–	0.01%	139
2022 Q3	$8K	Hold	200	–	–	0.01%	148
2022 Q2	$10K	Hold	200	–	–	0.01%	141
2022 Q1	$10K	Sell	200 -400	-67%	-$20.7K	0.01%	150
2021 Q4	$30K	Hold	600	–	–	0.03%	102
2021 Q3	$29K	Hold	600	–	–	0.03%	101
2021 Q2	$32K	Buy	600 +200	+50%	+$10.4K	0.04%	101
2021 Q1	$20K	Buy	+400	New	+$19.2K	0.02%	87

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Hoese & Co's SNY Position: Q2 2023 in Review

Hoese & Co sold out of Sanofi (SNY) in Q2 2023, closing a stake of 200 shares — an estimated $9.37K sold.

Hoese & Co first reported a position in SNY in Q1 2021 and held it in 9 quarters. The position peaked at $32K in Q2 2021. 672 funds tracked by Wall St. Rank hold SNY as of Q2 2023.

Hoese & Co reported no remaining Sanofi position as of Q2 2023 after selling out during the quarter.
Hoese & Co sold 200 Sanofi shares in Q2 2023, an estimated $9.37K.
Hoese & Co first reported a position in Sanofi in Q1 2021 and held it in 9 quarters.
Hoese & Co's Sanofi position peaked at $32K in Q2 2021.
672 funds tracked by Wall St. Rank held Sanofi as of Q2 2023.

Based on Hoese & Co's 13F filing for Q2 2023, filed 12 Jul 2023.